Abstract：
Purpose: This article illustrates the replication of asthma and COPD conditions in a laboratory setting and the potential applications of this methodology.
Introduction: Biologic drugs have been shown to enhance the treatment of severe asthma and COPD. Monoclonal antibodies against specific targets have dramatically changed the management of these conditions. Although the inflammatory pathways of asthma and COPD have already been clearly outlined, alternative mechanisms of action remain mostly unexplored. They could provide additional insights into these diseases and their clinical management.
Aims: In vivo or in vitro models have thus been developed to test alternative hypotheses. This study describes sophisticated ex vivo models that mimic the response of human respiratory mucosa to disease triggers, aiming to narrow the gap between laboratory studies and clinical practice.
Results: These models successfully replicate crucial aspects of these diseases, such as inflammatory cell presence, cytokine production, and changes in tissue structure, offering a dynamic platform for investigating disease processes and evaluating potential treatments, such as monoclonal antibodies. The proposed models have the potential to enhance personalized medicine approaches and patient-specific treatments, helping to advance the understanding and management of respiratory diseases.
Introduction: Biologic drugs have been shown to enhance the treatment of severe asthma and COPD. Monoclonal antibodies against specific targets have dramatically changed the management of these conditions. Although the inflammatory pathways of asthma and COPD have already been clearly outlined, alternative mechanisms of action remain mostly unexplored. They could provide additional insights into these diseases and their clinical management.
Aims: In vivo or in vitro models have thus been developed to test alternative hypotheses. This study describes sophisticated ex vivo models that mimic the response of human respiratory mucosa to disease triggers, aiming to narrow the gap between laboratory studies and clinical practice.
Results: These models successfully replicate crucial aspects of these diseases, such as inflammatory cell presence, cytokine production, and changes in tissue structure, offering a dynamic platform for investigating disease processes and evaluating potential treatments, such as monoclonal antibodies. The proposed models have the potential to enhance personalized medicine approaches and patient-specific treatments, helping to advance the understanding and management of respiratory diseases.
摘要：
生物药物已被证明可以增强严重哮喘和COPD的治疗。针对特定靶标的单克隆抗体极大地改变了这些病症的管理。虽然哮喘和COPD的炎症途径已经被清楚地概述，替代作用机制仍未被探索。他们可以为这些疾病及其临床管理提供更多见解。因此,已经开发了体内或体外模型来测试替代假设。这项研究描述了复杂的离体模型，模拟人类呼吸道粘膜对疾病触发因素的反应，旨在缩小实验室研究与临床实践之间的差距。这些模型成功地复制了这些疾病的关键方面，比如炎症细胞的存在，细胞因子产生，和组织结构的变化，为调查疾病过程和评估潜在治疗提供动态平台，如单克隆抗体。所提出的模型有可能增强个性化医疗方法和针对患者的治疗，帮助提高对呼吸系统疾病的理解和管理。本文说明了在实验室环境中哮喘和COPD疾病的复制以及该方法的潜在应用。
